News & Insights

Developers building spec life science properties in competitive markets face a hard question: Is your MEP infrastructure capable of supporting the tenants you’re marketing to? For many, the honest answer is no—not because the building is poorly constructed, but because life science development and pharmaceutical-grade manufacturing are not the same problem.

A spec building can have clean finishes, generous ceiling heights, and a floor plan that looks great in a leasing brochure, yet still require 18 months of infrastructure work before a cGMP operator can run a single batch. The gap shows up in predictable places, such as mechanical and clean facilities, process drainage, and HVAC system designs.

These are structural problems, and they are more expensive to solve after the fact than before. The developers who attract pharma tenants in competitive markets are those whose buildings and infrastructure are ready to support them before the lease conversation begins.

What “spec life science” often leaves out

The life science label covers a lot of ground. A chemistry quality control lab, a biologics manufacturing suite, and a contract development and manufacturing organization (CDMO) running multiple product types have little in common from an MEP standpoint. Developers who build for the former while marketing to the latter create a mismatch that surfaces the moment a serious pharma tenant starts due diligence.

A standard spec building typically includes domestic water, plant steam, basic compressed air, and standard electrical service. This is a reasonable starting point for research tenants, but a significant gap for pharmaceutical manufacturing. Pharma operations require purified water systems, clean steam, validated compressed air, and, in some cases, water for injection. Each of those systems carries a qualification burden. Installing them after construction means re-executing the installation, operational, and performance qualification work that should have happened once, in sequence, during the original build.

That qualification burden is what separates a pharma retrofit from a standard tenant improvement. In most industries, fixing an infrastructure gap is a construction problem. In pharmaceutical manufacturing, it’s a construction problem with a compliance tail. That tail adds time and cost that most developers don’t see coming when they underwrite a spec project.

Process drainage: the problem nobody sees until it’s too late

Of all the MEP systems that get overlooked in spec life science development, process drainage is the most consistent offender. It’s underground, invisible once the slab is poured, and rarely comes up in conversations focused on cleanroom layouts and finish specifications. However, it comes up later, when a pharma tenant walks through and asks where the process drains are.

In a slab-on-grade building with no basement access, that question has real consequences. Adding floor drains after the concrete is placed means cutting the slab, adding construction noise, dust, disruption, and a cost that dwarfs what the drainage would have cost if designed in from the start. Drain placement also follows the equipment layout, so coordination must happen before the pour. Rerouting that work after the fact is expensive by definition.

Material selection adds another layer. Pharmaceutical processes can discharge hot condensate from steam sterilization at temperatures that plastic drain lines simply can’t handle. Stainless steel is required in those cases, and that decision must be made before the floor goes down. Developers who treat drainage as a commodity item tend to get a hard education when their first pharma prospect starts asking detailed questions about discharge capacity and pipe materials.

HVAC for classified manufacturing is a different discipline

Laboratory HVAC and pharmaceutical manufacturing HVAC share a name and not much else. A cleanroom environment for biologics or fill-finish operations requires classifications ranging from Grade A through Grade D, each with defined air change rates, tightly controlled temperature and humidity, and specific pressure relationships between adjacent spaces.

These pressure cascades—the deliberate flow of air from cleaner zones into less clean ones—determine how the HVAC system is zoned, how many air handling units are needed, and how ductwork is routed. They are design decisions that shape the entire mechanical system, made early and once.

For developers targeting CDMOs or multi-tenant pharma use, the challenge compounds. Different product types, such as small molecules, biologics, and highly potent compounds, may require separate air-handling systems to prevent cross-contamination. A single HVAC zone serving a large open floor plate gives a CDMO operator no meaningful ability to run two product suites simultaneously without risking both.

Surface finishes are an important part of this picture, too. Cleanroom environments require seamless floors, non-shedding wall surfaces, and materials that can withstand repeated chemical cleaning. Specifying the right finishes during design costs a fraction of what replacing them later would, and it signals to pharma prospects that the developer understands the environment they’re building.

Designing for the tenant you haven’t met yet

In a dedicated pharmaceutical facility, material, personnel, and waste flows are designed around a known process. But in a spec building, the developer is designing for an unknown one. The question becomes: how do you design for GMP compliance when you don’t yet know what product will be manufactured there?

The answer is deliberate flexibility. Unidirectional flow—where materials, personnel, and waste move through the facility without crossing each other’s paths—is a foundational contamination control strategy, and a function of floor plan geometry. A floor plan that forces bidirectional traffic shifts the compliance burden onto the tenant, who must manage the risk through operating procedures rather than through facility design. Getting flow right means engaging process engineering during the floor plan phase, before the walls are set and utility chases are closed in.

For phased campuses, infrastructure strategy requires a specific kind of forward thinking. Distribution systems for utilities like purified water and clean steam are typically designed for the full eventual load from day one, because retrofitting distribution piping later is disruptive and expensive. Production capacity, such as boilers, chillers, and compressors, can be modularized and added in phases as demand grows. This allows developers to calibrate early-phase investment without building a backbone that later becomes a bottleneck.

Access is another design decision with long consequences. Utility chases, ceiling plenums, and service corridors that seem like minor details in commercial development become major cost drivers in a pharma retrofit. When a room sits in the middle of a production area with no adjacent service access, modifying utilities means working from below, above, or through occupied space—slower, more expensive, and harder to do cleanly.

The cost of getting it wrong

Retrofit economics in pharma are punishing in ways that don’t apply to other asset classes. The construction cost of cutting a slab or redesigning an HVAC system is real, but it’s only part of the picture. Every system that touches product quality requires formal documentation, commissioning, and qualification. If a utility must be replaced or significantly modified after occupancy, that qualification work gets repeated, ultimately costing more time, money, and a schedule that has already slipped.

In some cases, the math tips the analysis entirely. A building requiring extensive MEP remediation to meet pharma standards can reach a point where remediation costs approach the cost of new construction, and without the operational advantages of a facility designed correctly from the ground up. Serious pharma tenants run this analysis. They have options and choose accordingly.

How can Salas O’Brien help?

Getting pharma MEP right requires disciplines that don’t typically share a table during commercial real estate development: process engineering, mechanical and electrical engineering, cleanroom design, and commissioning and validation.

At Salas O’Brien, those capabilities are integrated, which means the decisions that affect each other get made together. Commissioning, qualification, and validation are considered from the earliest design conversations — not handed off in sequence after the design is already locked.

Our teams work across small molecules, biologics, fill-finish, and CDMO environments, which means you get engineering expertise alongside an understanding of the regulatory context that makes MEP decisions matter to pharma tenants. When you bring us in early in planning, the infrastructure decisions that define tenant quality are made at the right time, before they become expensive to change.

Ready to talk about your next pharma project? Reach out to one of our experts below, or contact us at [email protected].

For media inquiries on this article, reach out to [email protected].